Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Instem plc specializes in providing software solutions for the life sciences sector, particularly in drug development and regulatory compliance. Its competitive position is bolstered by a strong portfolio of proprietary software products, including the Provantis and Submit software, which streamline clinical trial processes and regulatory submissions across North America and Europe.
Instem generates revenue primarily through software licensing and subscription fees for its clinical trial management and regulatory compliance solutions. The company benefits from high switching costs due to its established client relationships and the critical nature of its software in the drug development process, providing a unique competitive advantage in a niche market.
New client acquisitions in North America and Europe
Regulatory changes impacting drug development processes
Expansion of product offerings, particularly in AI-driven analytics
Partnerships with major pharmaceutical companies
Technological disruption from emerging software solutions in clinical trial management
Regulatory changes that could impact the demand for existing services
Increased competition from larger software firms entering the healthcare space
Potential for price pressure as new entrants offer lower-cost solutions
Low liquidity due to current ratio of 0.93, which may limit operational flexibility
Dependence on a few key clients for a significant portion of revenue
moderate - The demand for healthcare information services is somewhat insulated from economic downturns, but overall spending in the healthcare sector can be influenced by GDP growth.
Interest rates affect Instem primarily through the cost of capital for potential acquisitions and investments in technology. Higher rates could dampen growth prospects if financing becomes more expensive.
minimal - The company has a low debt-to-equity ratio (0.02), indicating minimal reliance on external financing.
growth - Investors are likely attracted to Instem for its strong revenue growth and potential in the expanding healthcare technology market.
moderate - The stock has shown a 1-year return of 18.4%, indicating a moderate level of volatility.